We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Research · September 24, 2019

HyperAcute-Renal Immunotherapy for Salvage Treatment of mRCC

The Oncologist

 

Additional Info

The Oncologist
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma
Oncologist 2019 Sep 06;[EPub Ahead of Print], AW Hahn, C Drake, SR Denmeade, Y Zakharia, BL Maughan, E Kennedy, C Link, N Vahanian, H Hammers, N Agarwal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading